Kimmie Ng

Associate Professor of Medicine, Harvard Medical School

Dana-Farber Cancer Institute
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (24)

Year:

2026

Table S3. Sensitivity analysis of the association between plasma 25-hydroxyvitamin level and disease-free survival, overall survival, and time to recurrence, excluding patients who recurred or died within three months of blood collection

Year:

2025

Figure S3. Multivariable hazard ratio and 95% confidence intervals for disease-free survival (A), overall survival (B), and time to recurrence (C), comparing plasma 25-hydroxyvitamin D ≥12 versus

Year:

2025

Table S5. Hazard ratio of cancer-specific mortality by plasma 25-hydroxyvitamin D levels in plasma biomarker companion study and by predicted vitamin D scores in diet and lifestyle companion study

Year:

2025

Figure S2. Dose-response relationship and test of linearity for the hazard ratio (HR) of disease-free survival (A), overall survival (B), and time to recurrence (C) by continuous predicted vitamin D scores, with reference of plasma 25-hydroxyvitamin D set at 12 ng/ml

Year:

2025

Background The incidence of early-onset (EO) gastrointestinal (GI) cancers—commonly defined as being diagnosed in patients <50 years of age—is rising at an alarming rate globally. The rising incidence demonstrates a birth cohort effect, implicating environmental factors, such as diet and lifestyle; however, the drivers behind this trend are not yet known. Methods A comprehensive narrative review of the literature was conducted, focusing on EO colorectal, oesophagogastric, and pancreatic cancers. Additionally, the literature on less common EO GI cancers, including appendiceal, biliary, and neuroendocrine tumours, was reviewed. Epidemiological trends, risk factors, clinical and molecular characteristics, germline and somatic genetic features, and outcomes across these diseases were examined. Results EO GI cancers have demonstrated a consistent rise in incidence, which disproportionally affects black, Hispanic, and indigenous populations and women. Though germline pathogenic variants are more common in EO GI cancers compared with average-onset GI cancers, most cases occur sporadically. Modifiable risk factors associated with an increased risk of EO GI cancers include obesity, a Western-pattern diet, non-alcoholic fatty liver disease, smoking, and alcohol use, among others. Across GI cancers, younger patients frequently present with more aggressive disease features and receive more intensive treatment compared with older patients. Survival outcomes are inconsistent across studies. Conclusion EO GI cancers represent clinically distinct disease entities that are associated with unique challenges in screening, management, and survivorship. A better understanding of underlying aetiologies, optimized screening strategies, and improved survivorship support are necessary. Meeting the needs of this growing patient population will require a multidisciplinary, equity-based approach in both clinical care and research.

Year:

2025

Ovarian cancers and microsatellite stable (MSS) colorectal cancers are insensitive to anti–programmed cell death 1 (PD-1) immunotherapy, and new immunotherapeutic approaches are needed. Preclinical data suggest a relationship between immunotherapy resistance and elevated angiopoietin 2 levels. We performed a phase I dose escalation study of pembrolizumab and the angiopoietin 1/2 inhibitor trebananib (NCT03239145). This multicenter trial enrolled patients with metastatic ovarian cancer or MSS colorectal cancer. Trebananib was administered intravenously weekly for 12 weeks with 200 mg intravenous pembrolizumab every 3 weeks. The toxicity profile of this combination was manageable, and the protocol-defined highest dose level (trebananib 30 mg/kg weekly plus pembrolizumab 200 mg every 3 weeks) was declared the maximum tolerated dose. The objective response rate for all patients was 7.3% (90% confidence interval, 2.5%–15.9%). Three patients with MSS colorectal cancer had durable responses for ≥3 years. One responding patient’s colorectal cancer harbored a POLE mutation. The other two responding patients had left-sided colorectal cancers, with no baseline liver metastases, and genomic analysis revealed that they both had KRAS wild-type, ERBB2 -amplified tumors. After development of acquired resistance, biopsy of one patient’s KRAS wild-type ERBB2 -amplified tumor showed a substantial decline in tumor-associated T cells and an increase in immunosuppressive intratumoral macrophages. Future studies are needed to carefully assess whether clinicogenomic features, such as lack of liver metastases, ERBB2 amplification, and left-sided tumors, can predict increased sensitivity to PD-1 immunotherapy combinations.

Year:

2025

Current treatments for KRAS -mutant colorectal cancers are often limited by cellular plasticity and rewiring responses. Here we describe a promising therapeutic strategy that simultaneously targets epigenetic and oncogenic signals. Specifically, we show that inhibitors of histone methyltransferase, EZH2, synergize with various rat sarcoma virus (RAS) pathway inhibitors and promote dramatic tumor regression in vivo . Together these agents cooperatively suppress Wingless and Int-1 (WNT)-driven transcription and drive colorectal cancers into a more differentiated cell state by inducing the Groucho/transducin-like enhancer corepressor, TLE4 , along with a network of WNT pathway inhibitors and intestinal differentiation proteins. However, these agents also induce the proapoptotic protein BCL2 modifying factor (BMF), which subsequently kills these more differentiated cells. Accordingly, cell death can be prevented by activating β-catenin, by blocking differentiation, or by ablating BMF expression. Collectively, these studies reveal a new therapeutic approach for treating KRAS- mutant colorectal cancers and illustrate a critical convergence of EZH2 and RAS on oncogenic WNT signals, intestinal differentiation, and apoptosis. Significance: Combined EZH2 and RAS pathway inhibitors kill KRAS- mutant colorectal cancer cells and promote durable tumor regression in vivo . These agents function by cooperatively suppressing the WNT pathway, driving differentiation, and epigenetically reprogramming cells to permit the induction of apoptotic signals, which then kill these more differentiated tumor cells.

Year:

2024

Figure S3. Multivariable hazard ratio and 95% confidence intervals for disease-free survival (A), overall survival (B), and time to recurrence (C), comparing plasma 25-hydroxyvitamin D ≥12 versus

Year:

2024

Purpose: To assess whether higher plasma 25-hydroxyvitamin D (25[OH]D) are associated with improved outcomes in colon cancer and whether circulating inflammatory cytokines mediate such association. Patients and Methods: Plasma samples were collected from 1437 patients with stage III colon cancer enrolled in a phase III randomized clinical trial (CALGB/SWOG 80702) from 2010 to 2015, who were followed until 2020. Cox regressions were used to examine associations between plasma 25(OH)D and disease-free survival (DFS), overall survival (OS), and time to recurrence (TTR). Mediation analysis was performed for circulating inflammatory biomarkers of CRP, IL-6, and sTNF-R2. Results: Vitamin D deficiency (25(OH)D

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (37)

Juha Väyrynen

University of Oulu

FINLAND
View details

Hersh Gupta

Dana-Farber Cancer Institute

UNITED STATES
View details

Sandro Santagata

Brigham and Women's Hospital

UNITED STATES
View details

Annacarolina da Silva

Assistant Professor of Pathology and Laboratory Medicine

Weill Cornell Medical College

UNITED STATES
View details

En Cheng

Assistant Professor

Albert Einstein College of Medicine

UNITED STATES
View details

Livio Trusolino

Full Professor, University of Torino School of Medicine

Candiolo Cancer Institute, FPO-IRCCS

ITALY
View details

Aladdin Shadyab

Associate Professor

University of California, San Diego

UNITED STATES
View details

Pushpamali De Silva

Dana-Farber Cancer Institute

UNITED STATES
View details

Emma Welsh

Dana-Farber Cancer Institute

UNITED STATES
View details

Eileen M. O'Reilly

Attending

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Fred Tabung

University of South Carolina

UNITED STATES
View details

Qian Shi

Mayo Clinic

UNITED STATES
View details

Peter Kraft

Professor

Harvard T.H. Chan School of Public Health

UNITED STATES
View details

Kristian Helin

CEO, Professor

Institute of Cancer Research

UNITED KINGDOM
View details

Qiao-Li Wang

Affliated Researcher

Lund University

SWEDEN
View details

Karen Cichowski

Professor

Brigham and Women's Hospital

UNITED STATES
View details

Andrew D Cherniack

Group Leader

Dana-Farber Cancer Institute

UNITED STATES
View details

Jeffrey Clark

Associate Professor

Harvard University

UNITED STATES
View details

Srivatsan Raghavan

Assistant Professor

Dana-Farber Cancer Institute

UNITED STATES
View details

Bruno Bockorny

Beth Israel Deaconess Medical Center

UNITED STATES
View details

Scott Rodig

Professor of Pathology

Beth Israel Deaconess Medical Center

UNITED STATES
View details

Andrea Bertotti

Candiolo Cancer Institute

ITALY
View details

Peter Sorger

Otto Krayer Professor of Systems Pharmacology

Harvard Medical School

UNITED STATES
View details

Jean Wactawki-Wende

Dean, Suny Distinguished Professor

University at Buffalo

UNITED STATES
View details

JoAnn Manson

Professor

Harvard Medical School

UNITED STATES
View details

Elizabeth Cohen

Dana-Farber Cancer Institute

UNITED STATES
View details

Naiara Perurena

Group Leader

Instituto de Investigación Sanitaria Aragón

SPAIN
View details

Steven Corsello

Stanford University

UNITED STATES
View details

Sheheryar Kabraji

Associate Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Owen J. Sansom

Director

Cancer Research UK Beatson Institute

UNITED KINGDOM
View details

Thuy Mai Van Nguyen

Imperial College London

UNITED KINGDOM
View details

juhua luo

Professor

Indiana University Bloomington School of Public Health

UNITED STATES
View details

Chen Yuan

Assistant Professor

Cedars-Sinai Medical Center

UNITED STATES
View details

Priya Kumthekar

Northwestern Medicine

UNITED STATES
View details

Michael Rosenthal

Brigham and Women's Hospital

UNITED STATES
View details

Matthew Meyerson

Director, Center for Cancer Genomics

Dana-Farber Cancer Institute

UNITED STATES
View details

Nazmus Saquib

-

SAUDI ARABIA
View details